Haleos Labs Limited

Haleos Labs Limited Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Haleos Labs Limited

₹ 1,538 -0.90%
24 Jul - close price
haleoslabs.com BSE: 540679 NSE: HALEOSLABS
About

Incorporated in 2006, SMS Lifesciences Ltd is in the business of manufacturing of Active Pharma Ingredients and their intermediates[1]

Key Points

Business Overview:[1][2][3]
The company is the demerged entity of SMS Pharmaceuticals Ltd. It has a diversified product portfolio focused on the manufacturing of Active Pharmaceutical Ingredients (APIs) and intermediates, with offerings spanning several therapeutic segments, including gastro-intestinal, anti-ulcer, anti-hypertensive, erectile dysfunction, anti-convulsant, anti-infective, and more

Website BSE NSE
  • Market Cap ₹ 465 Cr.
  • Current Price ₹ 1,538
  • High / Low ₹ 1,778 / 1,050
  • Stock P/E 26.9
  • Book Value ₹ 706
  • Dividend Yield 0.10 %
  • ROCE 9.91 %
  • ROE 8.44 %
  • Face Value ₹ 10.0
Edit ratios

Pros

Cons

  • The company has delivered a poor sales growth of 4.68% over past five years.
  • Company has a low return on equity of 8.24% over last 3 years.
  • Company might be capitalizing the interest cost

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
63.73 74.65 69.26 72.05 89.99 92.55 78.46 84.60 89.11 82.50 81.37 94.78 75.14
61.45 72.11 61.33 62.75 78.63 76.27 69.89 71.85 81.69 70.79 67.79 80.73 70.98
Operating Profit 2.28 2.54 7.93 9.30 11.36 16.28 8.57 12.75 7.42 11.71 13.58 14.05 4.16
OPM % 3.58% 3.40% 11.45% 12.91% 12.62% 17.59% 10.92% 15.07% 8.33% 14.19% 16.69% 14.82% 5.54%
4.81 0.61 0.27 0.58 2.36 0.44 2.04 0.06 2.34 1.00 0.42 0.18 2.01
Interest 1.80 2.18 2.81 2.34 2.84 2.40 2.14 2.14 2.03 1.87 1.62 1.54 1.42
Depreciation 2.92 3.70 3.73 3.73 3.78 3.68 3.76 3.76 3.80 3.82 3.89 3.91 3.85
Profit before tax 2.37 -2.73 1.66 3.81 7.10 10.64 4.71 6.91 3.93 7.02 8.49 8.78 0.90
Tax % 10.55% 40.29% 126.51% -8.14% 8.73% 33.27% 29.72% 29.81% 11.45% 37.61% 24.38% 24.26% 62.22%
2.11 -3.83 -0.44 4.12 6.47 7.10 3.30 4.86 3.48 4.39 6.42 6.65 0.35
EPS in Rs 5.66 -5.95 2.25 14.22 19.52 23.15 15.45 18.09 9.82 13.76 20.18 21.90 1.46
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
378 261 266 350 316 306 345 334
343 235 235 316 287 275 300 289
Operating Profit 35 25 30 35 29 31 45 45
OPM % 9% 10% 11% 10% 9% 10% 13% 13%
2 2 2 14 5 4 5 2
Interest 6 5 5 6 7 10 9 6
Depreciation 6 8 8 10 11 15 15 15
Profit before tax 25 15 20 33 17 10 26 25
Tax % 30% 31% 31% 23% 31% 36% 28% 29%
18 10 14 25 11 6 19 18
EPS in Rs 59.04 33.67 44.85 83.75 37.91 30.07 66.52 57.26
Dividend Payout % 3% 0% 3% 2% 4% 5% 2% 3%
Compounded Sales Growth
10 Years: %
5 Years: 5%
3 Years: 2%
TTM: -3%
Compounded Profit Growth
10 Years: %
5 Years: 5%
3 Years: 20%
TTM: -14%
Stock Price CAGR
10 Years: %
5 Years: 16%
3 Years: 43%
1 Year: 30%
Return on Equity
10 Years: %
5 Years: 8%
3 Years: 8%
Last Year: 8%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 3 3 3 3 3 3 3 3
Reserves 103 113 126 149 166 174 194 211
47 65 65 80 100 101 86 111
116 72 108 125 126 114 107 130
Total Liabilities 270 253 302 357 395 391 390 454
118 124 130 142 228 223 232 268
CWIP 3 16 38 51 1 6 0 10
Investments 0 0 0 0 0 0 0 0
148 113 134 164 166 162 158 176
Total Assets 270 253 302 357 395 391 390 454

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
30 15 35 -11 15 24 34 37
-44 -27 -26 -7 -31 -18 -15 -58
15 12 -3 11 17 -7 -19 21
Net Cash Flow 1 -0 6 -8 0 -1 -0 1
Free Cash Flow 6 -9 -0 -53 -28 4 19 -21
CFO/OP 105% 69% 133% -10% 62% 88% 94% 98%

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 40 30 47 35 53 61 73 67
Inventory Days 116 149 164 159 184 196 160 210
Days Payable 140 101 163 146 127 143 126 162
Cash Conversion Cycle 16 78 48 48 110 115 106 116
Working Capital Days 14 18 2 17 24 11 7 5
ROCE % 12% 13% 12% 8% 7% 12% 10%

Insights

In beta
Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Capital Expenditure (Additions to Property, Plant & Equipment)
INR Lakhs

Log in to view insights

Please log in to see hidden values.

Login
Export Revenue Share
% of revenue ・Standalone data
Ranitidine HCl Share of Gross Sales
% of gross sales ・Standalone data
Top 5/6 Customers' Share of Gross Sales
% of gross sales ・Standalone data
R&D Expenditure
INR Lakhs ・Standalone data
Installed Capacity (Reactor Capacity)
KL
Production Volume (APIs and Intermediates)
MT ・Standalone data
R&D Team Size
Employees ・Standalone data
R&D Expenditure (Percentage of Turnover)
% ・Standalone data

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
70.32% 70.68% 71.19% 71.40% 71.40% 71.40% 71.40% 71.40% 71.40% 71.79% 72.10% 72.10%
0.00% 0.00% 0.00% 0.01% 0.02% 0.00% 0.00% 0.03% 0.00% 0.00% 0.00% 0.00%
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.03% 0.29% 0.30% 0.31%
29.68% 29.31% 28.81% 28.59% 28.57% 28.59% 28.60% 28.56% 28.57% 27.91% 27.59% 27.58%
No. of Shareholders 8,4438,2338,1167,8617,8497,6267,4797,4127,5217,1256,9376,859

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls

  • Jul 2025
    Transcript
    AI Summary
    PPT